Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Regorafenib

GRID

Bayer · Phase 3 · Completed · Enrollment 199

NCT01271712

ArmPopulationDoseEstimandComparatorEfficacy
Regorafenib 160 mg, 3 weeks on 1 offGIST after imatinib and sunitinib160 mgITTplacebomedian progression-free survival: 4.8 months, primary analysisprogression-free survival hazard ratio vs placebo: 0.27 HR, primary analysismedian overall survival: 17.4 months, final OS analysis, 162 events
PlaceboGIST after imatinib and sunitinibplaceboITTn/rmedian progression-free survival: 0.9 months, primary analysismedian overall survival: 17.4 months, final OS analysis; 88% crossed over